Trial · NCT07418879
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
NCT07418879, Not applicable, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC. Trials, record NCT07418879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07418879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
- NCT number
- NCT07418879
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Non-small Cell Lung Cancer, RET Fusion, Pralsetinib
- Interventions
- Pralsetinib, Leucogen
- First posted
- 2026-02-18
- Last updated
- 2026-02-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The grade and incidence of leukopenia and neutropenia at 1 month after the first administration of Pralsetinib | up to 24 months | Metric/method of measurement:Blood samples are collected at specified time points, and indicator values are obtained through routine blood tests. The results are graded according to the CTCAE 5.0 criteria, and finally the incidence of each grade is calculated. At 1 month after the first administration of Pralsetinib. Assessed |
| Secondary | The grade and incidence of Leukopenia and neutropenia at 2 months and 3 months after the first administration of Pralsetinib | up to 24 months | Metric/method of measurement:Blood samples are collected at specified time points, and indicator values are obtained through routine blood tests. The results are graded according to the CTCAE 5.0 criteria, and finally the incidence of each grade is calculated. At 2 months and 3 months after the first administration of Pralsetinib. |
| Secondary | Incidence of Grade 3 Treatment-Related Adverse Events (TRAE), and Incidence of Dose Interruption/Reduction/Disc continuation | up to 24 months | The incidence of Grade 3 Treatment-Related Adverse Events (TRAE) refers to the probability of recording treatment-related adverse events that meet the Grade 3 criteria of CTCAE Version 5.0 in subjects from the first administration to 28 days after the last administration, while the incidence of dose interruption/reduction/discontinuation refers to the probability of recording corresponding events caused by drug toxicity. |
| Secondary | Time to Treatment Failure (TTF) | up to 24 months | Time from the start of treatment to the first occurrence of a treatment failure event |
| Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items (EORTC QLQ-LC30) | Up to 24 months | EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Negative change from baseline scores indicates less symptom severity, and thus improvement on health status. |
| Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) | up to 24 months | QLQ-C30 has 30 questions and scores range from 0-100 after a linear transformation. Positive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07418879
GET https://conductscience.org/api/trials/v1/NCT07418879/registered